WO2003039472A3 - Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise - Google Patents

Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise Download PDF

Info

Publication number
WO2003039472A3
WO2003039472A3 PCT/US2002/035664 US0235664W WO03039472A3 WO 2003039472 A3 WO2003039472 A3 WO 2003039472A3 US 0235664 W US0235664 W US 0235664W WO 03039472 A3 WO03039472 A3 WO 03039472A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluid bed
compositions prepared
granulation process
bed granulation
intraorally disintegrating
Prior art date
Application number
PCT/US2002/035664
Other languages
English (en)
Other versions
WO2003039472A2 (fr
Inventor
Ken Yamamoto
Joseph P Reo
Koji Takahashi
Original Assignee
Pharmacia Corp
Ken Yamamoto
Joseph P Reo
Koji Takahashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Ken Yamamoto, Joseph P Reo, Koji Takahashi filed Critical Pharmacia Corp
Priority to EP02797073A priority Critical patent/EP1446088A2/fr
Priority to JP2003541764A priority patent/JP2005512990A/ja
Priority to BR0213973-1A priority patent/BR0213973A/pt
Priority to MXPA04004290A priority patent/MXPA04004290A/es
Priority to AU2002361596A priority patent/AU2002361596A1/en
Priority to CA002466030A priority patent/CA2466030A1/fr
Publication of WO2003039472A2 publication Critical patent/WO2003039472A2/fr
Publication of WO2003039472A3 publication Critical patent/WO2003039472A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)

Abstract

L'invention concerne des comprimés de Valdecoxib se désintégrant rapidement dans la bouche, ainsi que des procédés de préparation de ces formes posologiques. Les compositions selon l'invention sont utiles dans le traitement ou la prévention d'affections ou de troubles induits par la cyclooxygénase-2.
PCT/US2002/035664 2001-11-07 2002-11-07 Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise WO2003039472A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02797073A EP1446088A2 (fr) 2001-11-07 2002-11-07 Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise
JP2003541764A JP2005512990A (ja) 2001-11-07 2002-11-07 流動層造粒法により製造される口腔内崩壊型バルデコキシブ組成物
BR0213973-1A BR0213973A (pt) 2001-11-07 2002-11-07 Composições de valdecoxib que se desintegram intra-oralmente preparadas pelo processo de granulação em leito fluidizado
MXPA04004290A MXPA04004290A (es) 2001-11-07 2002-11-07 Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
AU2002361596A AU2002361596A1 (en) 2001-11-07 2002-11-07 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
CA002466030A CA2466030A1 (fr) 2001-11-07 2002-11-07 Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35017901P 2001-11-07 2001-11-07
US60/350,179 2001-11-07

Publications (2)

Publication Number Publication Date
WO2003039472A2 WO2003039472A2 (fr) 2003-05-15
WO2003039472A3 true WO2003039472A3 (fr) 2003-09-25

Family

ID=23375540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035664 WO2003039472A2 (fr) 2001-11-07 2002-11-07 Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise

Country Status (7)

Country Link
EP (1) EP1446088A2 (fr)
JP (1) JP2005512990A (fr)
AU (1) AU2002361596A1 (fr)
BR (1) BR0213973A (fr)
CA (1) CA2466030A1 (fr)
MX (1) MXPA04004290A (fr)
WO (1) WO2003039472A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146296A1 (fr) * 2006-06-12 2007-12-21 Schering Corporation Formulations et compositions pharmaceutiques d'un antagoniste sélectif de cxcr2, ou de cxcr1 et de cxcr2, et leurs procédés d'utilisation pour le traitement de troubles inflammatoires
CN101762646B (zh) * 2008-12-26 2012-09-05 扬子江药业集团有限公司 一种测定拉克替醇含量的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
WO2000032189A1 (fr) * 1998-11-30 2000-06-08 G. D. Searle & Co. Compositions a base de celecoxib
WO2001041761A2 (fr) * 1999-12-08 2001-06-14 Pharmacia Corporation Compositions de valdecoxib
WO2002015885A2 (fr) * 2000-08-18 2002-02-28 Pharmacia Corporation Formulation orale a desintegration rapide d'un inhibiteur de cyclooxygenase-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL187160B1 (pl) * 1994-01-31 2004-05-31 Yamanouchi Pharma Co Ltd Sposób wytwarzania rozpuszczalnej wewnątrzustnie formowanej tłocznie wypraski
JPH0867623A (ja) * 1994-08-31 1996-03-12 Taisho Pharmaceut Co Ltd 矯味経口製剤用組成物
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
PL351944A1 (en) * 1999-12-08 2003-07-14 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
WO2000032189A1 (fr) * 1998-11-30 2000-06-08 G. D. Searle & Co. Compositions a base de celecoxib
WO2001041761A2 (fr) * 1999-12-08 2001-06-14 Pharmacia Corporation Compositions de valdecoxib
WO2002015885A2 (fr) * 2000-08-18 2002-02-28 Pharmacia Corporation Formulation orale a desintegration rapide d'un inhibiteur de cyclooxygenase-2

Also Published As

Publication number Publication date
WO2003039472A2 (fr) 2003-05-15
JP2005512990A (ja) 2005-05-12
BR0213973A (pt) 2004-08-31
AU2002361596A1 (en) 2003-05-19
MXPA04004290A (es) 2004-08-11
EP1446088A2 (fr) 2004-08-18
CA2466030A1 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003026623A8 (fr) Compositions de valdecoxib se désintégrant dans la bouche
MXPA02006151A (es) Composiciones de liberacion dual de un inhibidor de ciclooxigenasa-2.
WO2005000298A3 (fr) Inhibiteurs de p-38
WO2003057144A3 (fr) Changement d'inhibiteurs de la dipeptidyl peptidase iv
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
TW200621765A (en) Substituted phenylaminothiazoles and their use
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
UA58576C2 (uk) Фармацевтична композиція, що містить целекоксиб
NO20052739L (no) CCR5-antagonister som medikamenter
WO2003044021A3 (fr) Composes de type indolizine substitues et leurs methodes d'utilisation
WO2004055010A3 (fr) Composes de cyclopropyle servant d'antagonistes de ccr5
MY128366A (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2003106450A8 (fr) Phenylaminopyrimidines et leur utilisation en tant qu'inhibiteurs de la rho-kinase
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2004009085A3 (fr) Comprimes de sumatriptan a gout masque et procedes de fabrication
WO2003039472A3 (fr) Compositions de valdecoxib a desintegration intra-buccale preparees au moyen d'un procede de granulation en lit fluidise
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
WO2002067894A3 (fr) Comprimes a dissolution rapide d'inhibiteurs de l'enzyme cyclooxygenase-2
WO2005011611A3 (fr) Composes bicycliques et compositions utilisees comme inhibiteurs pdf
WO2003000269A3 (fr) Nouvelle utilisation d'inhibiteurs de pde 10a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: PA/a/2004/004290

Ref document number: 2466030

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003541764

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002797073

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797073

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002797073

Country of ref document: EP